Compare · MSLE vs NVO
MSLE vs NVO
Side-by-side comparison of Satellos Bioscience Inc. (MSLE) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MSLE and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO carries a market cap of $220.35B.
- Over the past year, MSLE is down 40.4% and NVO is down 34.2% - NVO leads by 6.2 points.
- NVO has been more active in the news (5 items in the past 4 weeks vs 3 for MSLE).
- NVO has more recent analyst coverage (25 ratings vs 2 for MSLE).
- Company
- Satellos Bioscience Inc.
- Novo Nordisk A/S
- Price
- $7.08+1.29%
- $41.18+6.93%
- Market cap
- -
- $220.35B
- 1M return
- -0.98%
- +13.32%
- 1Y return
- -40.40%
- -34.24%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 3
- 5
- Recent ratings
- 2
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest MSLE
- SEC Form 6-K filed by Satellos Bioscience Inc.
- Satellos to Present at the Bloom Burton & Co. Healthcare Investor Conference
- Leerink Partners initiated coverage on Satellos Bioscience with a new price target
- SEC Form S-8 filed by Satellos Bioscience Inc.
- SEC Form 40-F filed by Satellos Bioscience Inc.
- SEC Form 6-K filed by Satellos Bioscience Inc.
- Satellos Reports 2025 Financial Results and Highlights Recent Company Progress
- Cantor Fitzgerald initiated coverage on Satellos Bioscience
- SEC Form 6-K filed by Satellos Bioscience Inc.
- Satellos Presents Interim SAT-3247 Clinical and Biomarker Data in Duchenne Muscular Dystrophy at the 2026 MDA Clinical & Scientific Conference
Latest NVO
- The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Wolfe Research initiated coverage on Novo Nordisk A/S